---
title: "Niki BioSolutions falls 5% as early 44% surge fades"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293650981.md"
description: "NIKI drops 5% in regular trading to $8.52, giving up most of its premarket gains after a gene-testing deal."
datetime: "2026-07-23T17:32:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293650981.md)
  - [en](https://longbridge.com/en/news/293650981.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293650981.md)
generator: "portal-rs"
---

# Niki BioSolutions falls 5% as early 44% surge fades

Niki BioSolutions(NIKI.US) 盘中跌**5.23%**，现报**8.52**美元。该股此前因子公司 DiamiR Biosciences 与 Progressive Medical Research 签署 APOE 基因检测服务协议盘前大涨超**44%**。

### Related Stocks

- [NIKI.US](https://longbridge.com/en/quote/NIKI.US.md)

## Related News & Research

- [Niki BioSolutions Highlights Strategic Synergies in Alzheimer’s Diagnostics](https://longbridge.com/en/news/298964729.md)
- [Aptorum’s Niki BioSolutions to present at H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/298315935.md)
- [Niki BioSolutions weighs financing options as going-concern warning clouds post-merger outlook](https://longbridge.com/en/news/296654125.md)
- [Aptorum files amended 8-K updating DiamiR Biosciences financial statements](https://longbridge.com/en/news/296654284.md)
- [Kira Sheinerman Secures Board Rights at Niki BioSolutions with 51.56% Stake](https://longbridge.com/en/news/293795714.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**